Colorectal carcinoma (CRC) · line 3 · Fruquintinib monotherapy (FRESCO-2) — 3L+ refractory metastatic CRC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-FRUQUINTINIB-CRC-3L |
| ID | IND-CRC-3L-FRUQUINTINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-CRC |
| Sources | SRC-ESMO-CRC-2024 SRC-FRESCO-2-DASARI-2023 SRC-NCCN-COLON-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ for chemo-refractory mCRC. NCCN Cat 1 (2025); FDA Nov 2023; EMA Jun 2024. SRC-FRESCO-2-DASARI-2023 source live in KB (Dasari Lancet 2023). Pairs with IND-CRC-METASTATIC-3L-REGORAFENIB and IND-CRC-METASTATIC-3L-TAS102-BEV in 3L+ mCRC sequencing landscape. Position vs TAS-102+bev: SUNLIGHT preferred 3L where accessible; fruquintinib 3L alternative if TAS-102 funding unavailable, OR fruquintinib 4L after TAS-102+bev. UA access: named-patient / EU cross-border only.
Used By
No reverse references found in the YAML corpus.